Pipeline Insight: ADHD

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-06-02

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The current ADHD market has long been saturated with traditional methylphenidate and amphetamine based drugs, with the only innovations being the development of extended release versions. However, the recent launch of Strattera (atomoxetine) has already shattered the traditional approach to drug therapy, opening the door for the uptake of new novel drug therapies.


Scope

  • Overview of the epidemiology, diagnosis and management of ADHD across the seven major pharmaceutical markets
  • Examination of the ADHD pipeline with in-depth clinical and commercial profiles of late-stage candidates, incorporating Datamonitor opinion
  • Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2015
  • Insight and commentary from qualitative interviews with ADHD opinion leaders in the US and Europe


    • Report Highlights
    The current global ADHD market is worth $2.7m and is expected to reach $3.4m by 2015, driven primarily by the launch of pipeline drugs and the continued growth of Strattera.

    Innovation is key - manufacturers can no longer expect significant returns on standard extended release formulations. The current pipeline offers drugs with novel delivery mechanisms; improved durations of action and anti-abuse profiles, which will help differentiate these pipeline drugs from the current established ADHD therapies.

    Although ADHD drugs have demonstrated significant efficacy in improving the three main symptoms of ADHD - inattention, hyperactivity and impulsivity - none have shown efficacy in treating the cognitive deficits of ADHD.


    Reasons to Purchase

  • Understand unmet needs in the ADHD market based on opinion leader comments regarding both currently marketed and pipeline products
  • Benchmark key late-stage ADHD compounds against current market leaders
  • Assess the global sales forecasts of late-stage pipeline drugs for ADHD and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: adhd adhd equasym pipeline xl drugs focalin swot adderall xr concerta

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.